SEC Tracker
Get the app

Janux Therapeutics JANX

Andrew Hollman Meyer director John Doe purchased 10,000 shares of JANX stock for a total transaction value of $250,000 on Nov 14, 2025. This insider buying activity signals a bullish sentiment from company leadership and could indicate confidence in the firm's future prospects.

Andrew Hollman Meyer, insider filing for JANX

Form
4
Filed
Importance
Routine

Open in the appGet the appView on EDGAR

Get an email when Janux Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Spyre Therapeutics SYRE public float $1.1B, Jun 30, 2025
  2. Schrodinger SDGR public float $1.1B, Jun 30, 2025
  3. Mannkind MNKD public float $1.1B, Jun 30, 2025
  4. Novavax NVAX public float $1.0B, Jun 30, 2025
  5. Harrow HROW public float $1.0B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.